Example: Heart Attack
Clinical Trials on Osteogenesis Imperfecta Type II
Total 1 results
-
NCT01061099CompletedConditions: Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III
We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
Show vendors
Sponsors and Collaborators
- GlaxoSmithKline
- National Cancer Institute (NCI)
- Pfizer
- AstraZeneca
- Assiut University
- Assistance Publique - Hôpitaux de Paris
- M.D. Anderson Cancer Center
- Mayo Clinic
- Cairo University
- National Institute of Allergy and Infectious Diseases (NIAID)
- Novartis Pharmaceuticals
- Massachusetts General Hospital
- Boehringer Ingelheim
- National Taiwan University Hospital
- Hoffmann-La Roche
- Merck Sharp & Dohme LLC
- Eli Lilly and Company
- University of California, San Francisco
- Stanford University
- Duke University
- View Full List